Beijing Jiashi Daheng Pharmaceutical Co. Ltd.

Primary Study Objectives To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of the test formulation of eplerenone tablets (50 mg, Sponsor: Beijing Chengji Pharmaceutical Co., Ltd.) and a reference formulation (Selara®, 50 mg, Licensee: Viatoris Pharmaceutical Co., Ltd.) in healthy Chinese adult subjects under fasting and fed conditions. Secondary Study Objectives To investigate the safety of the test formulation of eplerenone tablets (50 mg) and a reference formulation (Selara®, 50 mg) in healthy Chinese adult subjects.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the pharmacokinetic behavior of the test preparation propafenone hydrochloride tablets (specification: 100 mg, licensee: Beijing Chengji Pharmaceutical Co., Ltd.) and the reference preparation propafenone hydrochloride tablets (specification: 100 mg, licensee: TOA EIYO LTD., trade name: Pronon) in healthy subjects after oral administration in the fed state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation propafenone hydrochloride tablets and the reference preparation propafenone hydrochloride tablets in healthy subjects.

Primary objective: Using pharmacokinetic parameters as the primary endpoint evaluation index, the pharmacokinetic behavior of the test preparation propafenone hydrochloride tablets (specification: 100 mg, licensee: Beijing Chengji Pharmaceutical Co., Ltd.) and the reference preparation propafenone hydrochloride tablets (specification: 100 mg, licensee: TOA EIYO LTD., trade name: Pronon) in healthy subjects after oral administration under fasting state was compared to evaluate the bioequivalence of the two preparations. Secondary objective: To observe the safety of the test preparation propafenone hydrochloride tablets and the reference preparation propafenone hydrochloride tablets in healthy subjects.